Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension
Interventions: Medisafe; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Hypertensive Disorder of Pregnancy
Interventions: Postpartum Remote Physical Activity Intervention; Behavioral
Lead sponsor: Jackie Dziewior; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypertension, High Blood Pressure
Interventions: BPCARE Intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: San Diego, California

Conditions: Hypertension
Interventions: carvedilol; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions: inhaled nitric oxide, Placebo; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 23 Weeks to 29 Weeks
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Heart Failure, Hypertension
Interventions: Not listed
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Imperial, California

Conditions: Glaucoma
Interventions: Ranibizumab, Mitomycin (MMC); Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma, Coronary Artery Disease, Diabetes, Hypertension, Congestive Heart Failure
Interventions: Reports, Reports and Notices, Usual care; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 8,422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
Interventions: Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 7 Days to 30 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Hypertension
Interventions: Cardiopressin, Placebo; Dietary Supplement
Lead sponsor: Thorne HealthTech, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions: sildenafil; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Hypertension, Cancer, Lung Disease, Cardiothoracic Surgery
Interventions: Nesiritide (Natrecor), Right Heart Catheterization; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: TIVUS™ Renal Denervation System, Sham; Device · Other
Lead sponsor: SoniVie Inc.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 30 more

Conditions: Pulmonary Embolism, Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions: Catheter directed therapy, Systemic anticoagulation; Device · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Preeclampsia, Pregnancy
Interventions: Mitoquinol Mesylate, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension
Interventions: Irbesartan, Avapro; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypertension, Neonatal
Interventions: Boppli; Device
Lead sponsor: Indiana University; Other
Eligibility: 0 Months to 9 Months
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions: Hydrus Microstent, Ophthalmic surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hypertension
Interventions: Home Blood Pressure Monitoring; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypertension, Prehypertension, Overweight, Obesity, Hypertrophy, Left Ventricular
Interventions: Electronic Media Application, Standard of care education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Sitaxsentan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
Interventions: Intervention; Device
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Dothan, Alabama • Bakersfield, California • Bloomington, Minnesota + 1 more

Search by objective public record fields.

Medication Adherence Improvement Support App For Engagement - Blood Pressure

Remote Postpartum Intervention Targeting Movement Behaviors After Hypertensive Disorders of Pregnancy

Blood Pressure Care for Advancing Real-World Evidence (BPCARE)

Conditioned Pharmacotherapeutic Effects in Hypertension

Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia

Necklace-Shaped Sensor for Non-Invasive Remote Monitoring of Vitals

Lucentis Versus Mitomycin C During Glaucoma Surgery

Care Transitions for Complex Patient - Cycle 1 and Cycle 2

Ventilator Pressure and Optimization of Compliance and Hemodynamics

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

Nutraceutical Supplement in the Management of Hypertension

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

Natrecor in Pulmonary Hypertension

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone

MitoQ to Improve Vascular Funciton in Preeclampsia

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

Measurement of High Blood Pressure Using Boppli

Safety and Effectiveness of the Hydrus Microstent

A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients

Home Blood Pressure Monitoring Project

EMPower: Electronic Media Powering Positive Health Changes in Youth

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products